CR20150435A - Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor - Google Patents

Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor

Info

Publication number
CR20150435A
CR20150435A CR20150435A CR20150435A CR20150435A CR 20150435 A CR20150435 A CR 20150435A CR 20150435 A CR20150435 A CR 20150435A CR 20150435 A CR20150435 A CR 20150435A CR 20150435 A CR20150435 A CR 20150435A
Authority
CR
Costa Rica
Prior art keywords
benzoimidazol
histamine
receiver
modulators
pyrimidine
Prior art date
Application number
CR20150435A
Other languages
English (en)
Inventor
Magali B Hickey
Stefan Horns
Susanne Lochner
Matteo Conza
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR20150435A publication Critical patent/CR20150435A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42—Separation; Purification; Stabilisation; Use of additives
    • C07C51/43—Separation; Purification; Stabilisation; Use of additives by change of the physical state, e.g. crystallisation
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C30B7/08—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by cooling of the solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)

Abstract

Benzoimidazol-2-il pirimidinas, métodos de purificación para las mismas, y composiciones farmacéuticas y métodos para el tratamiento de estados de enfermedad, trastornos, y afecciones mediados por la actividad del receptor H4, que incluyen alergia, asma, enfermedades autoinmunitarias y prurito.
CR20150435A 2013-03-06 2015-08-24 Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor CR20150435A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361773706P 2013-03-06 2013-03-06
US201361776260P 2013-03-11 2013-03-11
US201361784909P 2013-03-14 2013-03-14
PCT/US2014/021130 WO2014138368A1 (en) 2013-03-06 2014-03-06 Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor

Publications (1)

Publication Number Publication Date
CR20150435A true CR20150435A (es) 2015-11-02

Family

ID=51488591

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20150435A CR20150435A (es) 2013-03-06 2015-08-24 Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor

Country Status (38)

Country Link
US (4) US8859575B2 (es)
EP (2) EP2964229B1 (es)
JP (1) JP6471103B2 (es)
KR (1) KR102230383B1 (es)
CN (1) CN105025898B (es)
AU (1) AU2014225675B2 (es)
BR (1) BR112015021463A8 (es)
CA (1) CA2903737C (es)
CL (1) CL2015002434A1 (es)
CR (1) CR20150435A (es)
CY (1) CY1122545T1 (es)
DK (1) DK2964229T3 (es)
DO (1) DOP2016000027A (es)
EA (1) EA201591648A1 (es)
ES (1) ES2773543T3 (es)
GT (1) GT201500243A (es)
HK (1) HK1218513A1 (es)
HR (1) HRP20200253T1 (es)
HU (1) HUE047681T2 (es)
IL (1) IL240247B (es)
JO (1) JO3516B1 (es)
LT (1) LT2964229T (es)
MX (1) MX2015011688A (es)
MY (1) MY180726A (es)
NZ (1) NZ710640A (es)
PE (1) PE20151536A1 (es)
PH (1) PH12015501731A1 (es)
PL (1) PL2964229T3 (es)
PT (1) PT2964229T (es)
RS (1) RS59909B1 (es)
SA (1) SA515360981B1 (es)
SG (1) SG11201507117XA (es)
SI (1) SI2964229T1 (es)
TW (1) TWI617554B (es)
UA (1) UA118754C2 (es)
UY (1) UY35370A (es)
WO (1) WO2014138368A1 (es)
ZA (1) ZA201507351B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51423B (en) 2006-03-31 2011-02-28 Janssen Pharmaceutica N.V. BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
MX2015011688A (es) 2013-03-06 2015-12-07 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
TWI644671B (zh) 2013-03-14 2018-12-21 比利時商健生藥品公司 Ｐ２ｘ７調節劑
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
TWI627174B (zh) 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
EP3321266A1 (en) 2013-03-14 2018-05-16 Janssen Pharmaceutica NV P2x7 modulators
EA034015B1 (ru) 2014-09-12 2019-12-19 Янссен Фармацевтика Нв Модуляторы р2х7
AU2017394032B8 (en) 2017-01-21 2020-10-22 Guangzhou Hanfang Pharmaceutical Co., Ltd. Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
JP7413368B2 (ja) 2018-09-28 2024-01-15 ヤンセン ファーマシューティカ エヌ．ベー． モノアシルグリセロールリパーゼ調節因子
CN113164459B (zh) 2018-09-28 2024-09-03 詹森药业有限公司 单酰基甘油脂肪酶调节剂
JP2022550767A (ja) 2019-09-30 2022-12-05 ヤンセン ファーマシューティカ エヌ．ベー． 放射線標識されたｍｇｌ ｐｅｔリガンド
KR20220157999A (ko) 2020-03-26 2022-11-29 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3005852A (en) 1959-12-22 1961-10-24 Gen Aniline & Film Corp Production of sulfoxides and sulfones
GB1062357A (en) 1965-03-23 1967-03-22 Pfizer & Co C Quinazolone derivatives
US3931195A (en) 1971-03-03 1976-01-06 Mead Johnson & Company Substituted piperidines
US4191828A (en) 1976-04-14 1980-03-04 Richardson-Merrell Inc. Process for preparing 2-(2,2-dicyclohexylethyl)piperidine
US4337341A (en) 1976-11-02 1982-06-29 Eli Lilly And Company 4a-Aryl-octahydro-1H-2-pyrindines
US4190601A (en) 1978-05-31 1980-02-26 Union Carbide Corporation Production of tertiary amines by reductive alkylation
JPS6130576A (ja) 1984-07-24 1986-02-12 Ube Ind Ltd ２−アミノ−５−シアノピリミジンの製法
GB9410031D0 (en) 1994-05-19 1994-07-06 Merck Sharp & Dohme Therapeutic agents
GB9422391D0 (en) 1994-11-05 1995-01-04 Solvay Interox Ltd Oxidation of organosulphur compounds
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
CA2250936A1 (en) 1996-04-03 1997-10-09 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0891351A1 (en) 1996-04-03 1999-01-20 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5880140A (en) 1996-04-03 1999-03-09 Merck & Co., Inc. Biheteroaryl inhibitors of farnesyl-protein transferase
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
WO1998031369A1 (fr) 1997-01-16 1998-07-23 Sekisui Chemical Co., Ltd. Preparations a usage externe a absorption percutanee
AU729869B2 (en) 1997-01-17 2001-02-15 Merck & Co., Inc. Integrin antagonists
US5945422A (en) 1997-02-05 1999-08-31 Warner-Lambert Company N-oxides of amino containing pyrido 2,3-D! pyrimidines
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
GB9801231D0 (en) 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
AU9663798A (en) 1997-10-06 1999-04-27 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
ATE245641T1 (de) 1998-02-17 2003-08-15 Tularik Inc Antivirale pyrimidinderivate
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
ATE242241T1 (de) 1999-03-25 2003-06-15 Synthon Bv Imidazopyridinderivate und verfahren zu ihrer herstellung
NZ516348A (en) 1999-06-23 2003-06-30 Aventis Pharma Gmbh Substituted benzimidazole
TWI279402B (en) 1999-08-20 2007-04-21 Banyu Pharma Co Ltd Spiro compounds having NPY antagonistic activities and agents containing the same
HUP0202678A3 (en) 1999-09-30 2004-06-28 Pfizer Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use
CN1623984A (zh) 1999-12-27 2005-06-08 日本烟草产业株式会社 稠环化合物及其药物用途
DE10006453A1 (de) 2000-02-14 2001-08-16 Bayer Ag Piperidylcarbonsäuren als Integrinantagonisten
CN1592621A (zh) * 2000-04-24 2005-03-09 特瓦制药工业有限公司 唑吡坦半酒石酸盐
DE60125429T2 (de) * 2000-04-24 2007-09-27 Teva Pharmaceutical Industries Ltd. Zolpidem hemitartrat solvat
EP1296977A1 (en) 2000-06-23 2003-04-02 Bristol-Myers Squibb Pharma Company Heteroaryl-phenyl substituted factor xa inhibitors
AU2001289615A1 (en) 2000-06-28 2002-01-08 Thromb-X N.V. Pluripotent embryonic stem (es) cell lines, improved methods for their production, and their use for germ line transmission and for the generation of genetically modified animals
BR0112712A (pt) 2000-07-21 2003-05-20 Syngenta Partcipations Ag Processo para preparação de 4,6-dimetóxi-2-(metilsulfonil)-1,3-pirimidina
KR100816769B1 (ko) 2000-09-06 2008-03-26 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 글리코겐 합성효소 키나아제 3의 억제제
CA2430037A1 (en) 2000-11-20 2002-05-30 Michael S. South Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade
WO2002064096A2 (en) 2001-02-16 2002-08-22 Tularik Inc. Methods of using pyrimidine-based antiviral agents
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
AU2002247402A1 (en) 2001-03-23 2002-10-08 Chugai Seiyaku Kabushiki Kaisha Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
US20050107400A1 (en) 2001-03-30 2005-05-19 Boyd Leslie F. Use of pyrazolopyridines as therapeutic compounds
US6858600B2 (en) 2001-05-08 2005-02-22 Yale University Proteomimetic compounds and methods
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US7141572B2 (en) * 2001-11-05 2006-11-28 Merck Patent Gesellschaft Hydrazono-malonitriles
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
US7148236B2 (en) 2002-01-17 2006-12-12 Merck & Co., Inc. Modulators of acetylcholine receptors
TWI270542B (en) 2002-02-07 2007-01-11 Sumitomo Chemical Co Method for preparing sulfone or sulfoxide compound
US7314937B2 (en) 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
WO2004012736A1 (en) 2002-08-02 2004-02-12 Genesoft Pharmaceuticals, Inc. Biaryl compounds having anti-infective activity
EP1551406A1 (en) 2002-09-06 2005-07-13 Janssen Pharmaceutica N.V. Use of indolyl derivatives for the manufacture of a medicament for the treatment of allergic rhinitis
US20040127395A1 (en) 2002-09-06 2004-07-01 Desai Pragnya J. Use of histamine H4 receptor modulators for the treatment of allergy and asthma
DE60305052T2 (de) 2002-09-06 2006-12-21 Janssen Pharmaceutica N.V. Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
CA2497827A1 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
EP1546115A4 (en) 2002-09-27 2010-08-04 Merck Sharp & Dohme SUBSTITUTED PYRIMIDINES
TW200501960A (en) 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
US20040105856A1 (en) 2002-12-02 2004-06-03 Robin Thurmond Use of histamine H4 receptor antagonist for the treatment of inflammatory responses
BRPI0409986A (pt) 2003-05-05 2006-05-09 Hoffmann La Roche derivados de pirimidina fundida com atividade de crf
KR20060023529A (ko) 2003-05-14 2006-03-14 토레이파인스 테라퓨틱스, 인코포레이티드 화합물 및 아밀로이드 베타를 변조하는데 있어서 그의 용도
SE0302116D0 (sv) 2003-07-21 2003-07-21 Astrazeneca Ab Novel compounds
MXPA05013637A (es) 2003-08-13 2006-02-24 Chiron Corp Inhibidores gsk-3 y usos de los mismos.
BRPI0414581C1 (pt) 2003-09-22 2021-05-25 Mei Pharma Inc composto, composição farmacêutica compreendendo o referido composto e uso do referido composto
CA2540638A1 (en) 2003-09-30 2005-04-14 Janssen Pharmaceutica N.V. Quinoxaline compounds
US7432378B2 (en) 2003-09-30 2008-10-07 Janssen Pharmaceutica, N.V. Benzoimidazole compounds
WO2005032490A2 (en) 2003-10-08 2005-04-14 Bristol-Myers Squibb Company Cyclic diamines and derivatives as factor xa inhibitors
JPWO2005040135A1 (ja) 2003-10-24 2007-03-08 小野薬品工業株式会社 抗ストレス薬およびその医薬用途
US8277831B2 (en) 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
CA2560896C (en) 2004-03-25 2013-06-18 Janssen Pharmaceutica, N.V. Imidazole compounds
JPWO2005115993A1 (ja) 2004-05-31 2008-03-27 萬有製薬株式会社 キナゾリン誘導体
ES2362102T3 (es) 2004-06-30 2011-06-28 Janssen Pharmaceutica Nv Eteres de bencimidazol e imidazopiridina sustituidos con arilo como agentes anticáncer.
EP1790650B1 (en) 2004-08-31 2014-03-26 Msd Kk NEW SUBSTITUTED IMIDAZOLE DERIVATIVES
US7906528B2 (en) 2004-10-05 2011-03-15 Novartis International Pharmaceutical Ltd. Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds
US7381732B2 (en) 2004-10-26 2008-06-03 Bristol-Myers Squibb Company Pyrazolobenzamides and derivatives as factor Xa inhibitors
US7442716B2 (en) 2004-12-17 2008-10-28 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic)-1H-phenantrho[9,10-d]imidazoles as mPGES-1 inhibitors
CN101119973B (zh) 2004-12-17 2011-08-03 默克弗罗斯特加拿大有限公司 作为mPGES-1抑制剂的2-(苯基或者杂环基)-1H-菲并[9,10-d]咪唑类化合物
AU2006226775A1 (en) 2005-03-24 2006-09-28 Janssen Pharmaceutica, N.V. Biaryl derived amide modulators of vanilloid VR1 receptor
WO2007044085A2 (en) 2005-05-19 2007-04-19 Xenon Pharmaceuticals Inc. Heteroaryl compounds and their uses as therapeutic agents
US8193206B2 (en) 2005-06-14 2012-06-05 Taigen Biotechnology Co., Ltd. Pyrimidine compounds
US20060281712A1 (en) 2005-06-14 2006-12-14 Chi-Feng Yen Pyrimidine compounds
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
BRPI0615880A2 (pt) 2005-09-13 2011-05-31 Palau Pharma Sa compostos derivados de 2-aminopirimidina como moduladores da atividade de receptor da histamina h4, uso dos mesmos e composição farmacêutica
AR056560A1 (es) 2005-10-06 2007-10-10 Astrazeneca Ab Pirrolopiridinonas como moduladores cb1
EP1954287B2 (en) 2005-10-31 2016-02-24 Merck Sharp & Dohme Corp. Cetp inhibitors
US20090182142A1 (en) 2005-12-02 2009-07-16 Shigeru Furukubo Aromatic Compound
US20090286772A1 (en) 2006-02-24 2009-11-19 Anh Chau 2-(Phenyl or Heterocyclic)-1H-Phenanthro[9,10-D]Imidazoles
EP2004188B1 (en) 2006-03-31 2010-09-01 Janssen Pharmaceutica NV Benzoimidazol-2-yl pyridines as modulators of the histamine h4 receptor
RS51423B (en) 2006-03-31 2011-02-28 Janssen Pharmaceutica N.V. BENZOIMIDAZOL-2-IL PYRIMIDINI I KAO PYRAZID MODULATORS HISTAMINSKOG H4 RECEPTOR
JP5132673B2 (ja) 2006-04-07 2013-01-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ４受容体のモジュレーターとしてのインドールおよびベンゾイミダゾール
US20090069343A1 (en) 2006-04-10 2009-03-12 Dunford Paul J Combination Histamine H1R and H4R Antagonist Therapy for Treating Pruritus
US20090192158A1 (en) 2006-05-02 2009-07-30 Stacia Kargman Methods for Treating or Preventing Neoplasias
US20090209571A1 (en) 2006-05-18 2009-08-20 Bernard Cote Phenanthrene derivatives as MPGES-1 inhibitors
CL2007002007A1 (es) 2006-07-11 2008-08-22 Janssen Pharmaceutica Nv Compuestos derivados de benzofuro y benzotienopirimidinas, moduladores del receptor de histamina h4; procedimiento de preparacion; y su uso para tratar trastornos inflamatorios, alergicos, dermatologicos, enfermedades autoinmune, linfaticas y de inmu
US8779154B2 (en) * 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
TW200904437A (en) 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
AR069480A1 (es) 2007-11-30 2010-01-27 Palau Pharma Sa Derivados de 2-amino-pirimidina
WO2009079001A1 (en) 2007-12-18 2009-06-25 Janssen Pharmaceutica N.V. Bicyclic heteroaryl-substituted imidazoles as modulators of the histamine h4 receptor
PE20110061A1 (es) 2008-06-12 2011-01-31 Janssen Pharmaceutica Nv Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina
CA2727627C (en) 2008-06-12 2018-02-13 Janssen Pharmaceutica Nv Use of histamine h4 antagonist for the treatment of post-operative adhesions
ES2538135T3 (es) 2008-06-30 2015-06-17 Janssen Pharmaceutica N.V. Proceso para la preparación de derivados sustituidos de pirimidina
BRPI0913989A2 (pt) * 2008-06-30 2015-10-20 Janssen Pharmaceutica Nv processo para preparação de derivados de benzoimidazol-2-il pirirmidina
WO2010025314A2 (en) * 2008-08-28 2010-03-04 The General Hospital Corporation Prevention and treatment of itch with cysteine protease inhibition
IT1395963B1 (it) * 2009-06-04 2012-11-02 Rottapharm Spa Forme cristalline di 6-(1h-imidazol-1-il)-2-fenil chinazolina e dei suoi sali
TWI519533B (zh) 2010-11-01 2016-02-01 Ｌｇ生命科學有限公司 １－｛（２Ｓ）－２－胺基－４－［２，４－雙（三氟甲基）－５，８－二氫吡啶并［３，４－ｄ］嘧啶－７（６Ｈ）－基］－４－側氧丁基｝－５，５－二氟哌啶－２－酮酒石酸鹽之水合物
EP2465498A1 (en) * 2010-11-23 2012-06-20 Faes Farma, S.A. Diphenyl-amine derivatives: uses, process of synthesis and pharmaceutical compositions
MX2015011688A (es) 2013-03-06 2015-12-07 Janssen Pharmaceutica Nv Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.

Also Published As

Publication number Publication date
UY35370A (es) 2014-09-30
CN105025898A (zh) 2015-11-04
CY1122545T1 (el) 2021-01-27
US9278952B2 (en) 2016-03-08
ES2773543T3 (es) 2020-07-13
MY180726A (en) 2020-12-08
US20140364607A1 (en) 2014-12-11
US8859575B2 (en) 2014-10-14
PH12015501731B1 (en) 2015-10-19
CL2015002434A1 (es) 2016-02-05
SG11201507117XA (en) 2015-10-29
PH12015501731A1 (en) 2015-10-19
SA515360981B1 (ar) 2016-06-23
BR112015021463A8 (pt) 2019-11-19
JP6471103B2 (ja) 2019-02-13
EP2964229B1 (en) 2019-12-11
ZA201507351B (en) 2017-08-30
KR20150126881A (ko) 2015-11-13
MX2015011688A (es) 2015-12-07
SI2964229T1 (sl) 2020-02-28
HUE047681T2 (hu) 2020-05-28
US9434715B2 (en) 2016-09-06
US20160340337A1 (en) 2016-11-24
DK2964229T3 (da) 2020-01-27
EP2964229A1 (en) 2016-01-13
PT2964229T (pt) 2020-03-23
US20160159775A1 (en) 2016-06-09
HRP20200253T1 (hr) 2020-05-29
CN105025898B (zh) 2018-01-23
TWI617554B (zh) 2018-03-11
UA118754C2 (uk) 2019-03-11
WO2014138368A1 (en) 2014-09-12
GT201500243A (es) 2015-11-18
DOP2016000027A (es) 2017-04-30
EP2964229A4 (en) 2016-11-16
RS59909B1 (sr) 2020-03-31
PL2964229T3 (pl) 2020-05-18
NZ710640A (en) 2019-03-29
CA2903737C (en) 2021-05-18
IL240247B (en) 2019-06-30
EP3660011A1 (en) 2020-06-03
KR102230383B1 (ko) 2021-03-23
PE20151536A1 (es) 2015-10-28
US20140256942A1 (en) 2014-09-11
IL240247A0 (en) 2015-09-24
LT2964229T (lt) 2020-02-10
JO3516B1 (ar) 2020-07-05
CA2903737A1 (en) 2014-09-12
US9663497B2 (en) 2017-05-30
EA201591648A1 (ru) 2016-02-29
AU2014225675A1 (en) 2015-08-13
HK1218513A1 (zh) 2017-02-24
BR112015021463A2 (pt) 2017-07-18
JP2016510752A (ja) 2016-04-11
TW201516042A (zh) 2015-05-01
AU2014225675B2 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
CR20150435A (es) Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor
UY30253A1 (es) Benzoimidazol -2-il pirimidinas y pirazinas como moduladores del receptor h4 de histamina
ECSP099582A (es) Moduladores 2-aminopirimidina del receptor de histamina h4
CL2018000039A1 (es) Derivados de oxopiridina sustituidos
CO6321192A2 (es) Moduladores de diamino-piridina pirimidina y piridazina del receptor h4 de histamina
DOP2016000295A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
CR20160501A (es) Derivados de quinoxalina útiles como amortiguadores del receptor del factor de crecimiento de fibroblastos (fgfr) cinasa
DOP2014000194A (es) COMPUESTOS DE OXAZOLIDIN- 2- ONA Y USOS DE LOS MISMOS COMO INHIBIDORES DE LA PI3Ks
TR201901886T4 (tr) DNA-PK inhibitörleri.
TN2015000120A1 (en) Oxazolidin-2-one-pyrimidine derivatives
CR20140257A (es) Nuevos 2h-indazoles como antagonistas del receptor ep2
DOP2014000295A (es) N-[4-(quinolin-4-iloxi)ciclohexil(metil)](hetero)aril-carboxamidas como antagonistas del receptor de andrógenos, su producción y usos como productos medicinales
DOP2015000290A (es) Benzoxazoles sustituidos
AR095033A1 (es) Moduladores benzoimidazol-2-il pirimidina modulares del receptor de histamina h₄
CU20140102A7 (es) Compuestos de oxazolidin-2- ona y usos de los mismos como inhibidores de la p13ks